ES2158452T3 - Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos. - Google Patents

Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.

Info

Publication number
ES2158452T3
ES2158452T3 ES97308862T ES97308862T ES2158452T3 ES 2158452 T3 ES2158452 T3 ES 2158452T3 ES 97308862 T ES97308862 T ES 97308862T ES 97308862 T ES97308862 T ES 97308862T ES 2158452 T3 ES2158452 T3 ES 2158452T3
Authority
ES
Spain
Prior art keywords
aterosclerosis
agronists
strogens
antagonists
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97308862T
Other languages
English (en)
Inventor
Robert Joseph Aiello
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2158452T3 publication Critical patent/ES2158452T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A47—FURNITURE; DOMESTIC ARTICLES OR APPLIANCES; COFFEE MILLS; SPICE MILLS; SUCTION CLEANERS IN GENERAL
    • A47J—KITCHEN EQUIPMENT; COFFEE MILLS; SPICE MILLS; APPARATUS FOR MAKING BEVERAGES
    • A47J47/00—Kitchen containers, stands or the like, not provided for in other groups of this subclass; Cutting-boards, e.g. for bread
    • A47J47/02—Closed containers for foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE DESCRIBE EL USO DE UN COMPUESTO DE FORMULA (I), EN LA CUAL A ES CH SUB,2} O NR, EN LA CUAL R ES H O ALQUILO C SUB,1} C SUB,6}; B, D Y E SON CADA UNO CH O N; Y, Z SUP,1} Y G SON CIERTOS SUSTITUYENTES MENCIONADOS; Y E ES 0, 1 O 2; PARA LA PREPARACION DE UN MEDICAMENTO PARA TRATAR LA ATEROSCLEROSIS.
ES97308862T 1996-11-15 1997-11-05 Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos. Expired - Lifetime ES2158452T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3127396P 1996-11-15 1996-11-15

Publications (1)

Publication Number Publication Date
ES2158452T3 true ES2158452T3 (es) 2001-09-01

Family

ID=21858549

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97308862T Expired - Lifetime ES2158452T3 (es) 1996-11-15 1997-11-05 Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.

Country Status (17)

Country Link
US (1) US6034102A (es)
EP (1) EP0842661B1 (es)
JP (1) JP3287793B2 (es)
KR (1) KR100367793B1 (es)
AT (1) ATE202702T1 (es)
AU (1) AU740378B2 (es)
CA (1) CA2221114C (es)
DE (1) DE69705480T2 (es)
DK (1) DK0842661T3 (es)
ES (1) ES2158452T3 (es)
GR (1) GR3036455T3 (es)
HU (1) HU223942B1 (es)
IL (1) IL122123A (es)
MY (1) MY114586A (es)
NZ (1) NZ329174A (es)
PT (1) PT842661E (es)
ZA (1) ZA9710292B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US6331562B1 (en) 1998-12-30 2001-12-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6291456B1 (en) 1998-12-30 2001-09-18 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ， インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
CO5170459A1 (es) * 1999-06-01 2002-06-27 Pfizer Prod Inc Terapia transdermica con agonistas-antagonistas de estrogenos len-ol, administrados mediante medios transdermicos
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
HUP0202592A3 (en) * 2000-06-01 2003-07-28 Watson Pharmaceuticals Inc Cor Transdermal delivery of lasofoxifene
WO2002018954A2 (en) 2000-08-30 2002-03-07 Chemocentryx, Inc. Inhibition of cmv infection and dissemination
IL145876A0 (en) 2000-10-17 2002-07-25 Pfizer Prod Inc Methods and kits for improving vascular health
CA2429817C (en) 2000-11-24 2013-02-12 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
AU2002221116A1 (en) * 2000-12-11 2002-06-24 Takeda Chemical Industries Ltd. Medicinal compositions having improved water-solubility
WO2002062296A2 (en) * 2001-02-02 2002-08-15 Chemocentryx, Inc. Methods and compositions useful for stimulating an immune response
EP1465488A4 (en) * 2001-08-30 2007-04-18 Chemocentryx Inc ARYLAMINES AS INHIBITORS OF THE BINDING OF CHEMOKINE A US28
WO2008101133A2 (en) * 2007-02-14 2008-08-21 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100021455A1 (en) * 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
WO2010039931A2 (en) * 2008-10-01 2010-04-08 Cedars-Sinai Medical Center Methods of using il17rd and il23-il17 pathway genes to diagnose crohn's disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8486640B2 (en) 2007-03-21 2013-07-16 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (IPAA) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110189685A1 (en) * 2008-10-22 2011-08-04 Cedars-Sinai Medical Center Methods of using jak3 genetic variants to diagnose and predict crohn's disease
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
JP7082945B2 (ja) 2016-03-17 2022-06-09 シーダーズ―シナイ メディカル センター Ｒｎａｓｅｔ２により炎症性腸疾患を診断する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4320898A1 (de) * 1993-06-24 1995-01-05 Denecke Rainer Dr Med Vet Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

Also Published As

Publication number Publication date
MY114586A (en) 2002-11-30
KR19980042432A (ko) 1998-08-17
JPH10147527A (ja) 1998-06-02
PT842661E (pt) 2001-10-30
ZA9710292B (en) 1999-05-17
JP3287793B2 (ja) 2002-06-04
EP0842661A2 (en) 1998-05-20
HU9702040D0 (en) 1998-01-28
GR3036455T3 (en) 2001-11-30
IL122123A0 (en) 1998-04-05
DE69705480T2 (de) 2001-10-31
US6034102A (en) 2000-03-07
HU223942B1 (hu) 2005-03-29
NZ329174A (en) 2000-10-27
CA2221114A1 (en) 1998-05-15
DK0842661T3 (da) 2001-09-24
AU4523797A (en) 1998-05-21
EP0842661A3 (en) 1998-09-02
EP0842661B1 (en) 2001-07-04
AU740378B2 (en) 2001-11-01
CA2221114C (en) 2003-10-28
IL122123A (en) 2001-07-24
ATE202702T1 (de) 2001-07-15
KR100367793B1 (ko) 2003-04-21
HUP9702040A1 (hu) 2000-11-28
DE69705480D1 (de) 2001-08-09

Similar Documents

Publication Publication Date Title
ES2158452T3 (es) Uso de agonistas y antagonistas de estrogenos en la fabricacion de un medicamento para el tratamiento de la ateroesclerosis, independientemente de la disminucion de lipidos.
EA200000592A1 (ru) Азаполициклические соединения, конденсированные с арилом
ATE68495T1 (de) 4,5,6,7-tetrahydro-1h-imidazo(4,5c>pyridinderivate und analoge mit antihypertensiver wirkung.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
EA199700117A1 (ru) Трициклические бензазепиновые антагонисты вазопрессина, способ их получения, фармацевтическая композиция и способ лечения млекопитающих с использованием трициклических бензазепинов
AR001413A1 (es) Compuestos triciclicos de carbamato, utiles para la inhibición de la función de la proteina g y paratratamiento de enfermedades proliferativas.
SE9702564D0 (sv) New compounds
EA200000996A1 (ru) Конденсированные с арилом азаполициклические соединения
ES2037670T3 (es) Procedimiento para la preparacion de complejos de (2,2-bis(aminometil)-1,3-propanodiol-n,n') platino.
ATE126205T1 (de) Disubstituierte arylverbindungen welche eine selektive leukotrien-b4 antagonistische aktivität aufweisen.
NO975028D0 (no) Piperazinoderivater som neurokininantagonister
ES2061811T3 (es) Uso de compuestos de gamma-oxibutenolido conjugados para tratar ulcera.
ATE117980T1 (de) Serotonin-antagonisten.
KR950700684A (ko) 시클릭 항-종양 촉진제 화합물, 그의 조성물, 제조 방법 및 용도(Cyclic Anti-Tumor Promoter Compounds, Compositions and Methods for Production and Use)
FR2599036B1 (fr) Nouveaux derives de synergistines, leur preparation et les compositions pharmaceutiques qui les contiennent
ATE100465T1 (de) Analoge von bradykinin, dessen synthese und dessen benutzung in der therapie.
DE3382452D1 (de) Pharmakologisch wirksame pyrazolopyridine.
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
DE69810340D1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
ES2049703T3 (es) Derivados sulfurados de acidos biliares.
MX9203362A (es) Composicion diuretica de benazepril/tiazida de dosis baja, para el tratamiento de la hipertension
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
ATE85056T1 (de) Tetracyclische indolderivate.
ATE109483T1 (de) Alpha-adrenergische rezeptorantagonisten.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 842661

Country of ref document: ES